We developed a viral vector Ad5/35-CAG-mBDNF expressing the mature form of BDNF (mBDNF). On the basis of olfactory ensheathing cells transduced with this adenovector, a new gene-cell construct was obtained. In experiments in vitro, high viability of the transduced olfactory ensheathing cells and enhanced secretion of BDNF by these cells were observed. It is possible that a new gene-cell construct will significantly increase the regenerative effects of transplanted olfactory ensheathing cells.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baldo A, van den Akker E, Bergmans HE, Lim F, Pauwels K. General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination. Curr. Gene Ther. 2013;13(6):385-394. https://doi.org/10.2174/15665232113136660005
Baseri B, Choi JJ, Deffieux T, Samiotaki G, Tung YS, Olumolade O, Small SA, Morrison B, Konofagou EE. Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood-brain barrier using focused ultrasound and microbubbles. Phys. Med. Biol. 2012;57(7):N65-N81. https://doi.org/10.1088/0031-9155/57/7/N65
Bradbury EJ, Burnside ER. Moving beyond the glial scar for spinal cord repair. Nat. Commun. 2019;10(1):3879. https://doi.org/10.1038/s41467-019-11707-7
Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target Ther. 2021;6(1):53. https://doi.org/10.1038/s41392-021-00487-6
Carwardine D, Prager J, Neeves J, Muir EM, Uney J, Granger N, Wong LF. Transplantation of canine olfactory ensheathing cells producing chondroitinase ABC promotes chondroitin sulphate proteoglycan digestion and axonal sprouting following spinal cord injury. PLoS One. 2017;12(12):e0188967. https://doi.org/10.1371/journal.pone.0188967
Cho YS, Do MH, Kwon SY, Moon C, Kim K, Lee K, Lee SJ, Hemmi S, Joo YE, Kim MS, Jung C. Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers. Oncotarget. 2016;7(25):38210-38223. https://doi.org/10.18632/oncotarget.9427
Cloutier F, Kalincik T, Lauschke J, Tuxworth G, Cavanagh B, Meedeniya A, Mackay-Sim A, Carrive P, Waite P. Olfactory ensheathing cells but not fibroblasts reduce the duration of autonomic dysreflexia in spinal cord injured rats. Auton. Neurosci. 2016;201:17-23. https://doi.org/10.1016/j.autneu.2016.08.015
DiPaolo N, Ni S, Gaggar A, Strauss R, Tuve S, Li ZY, Stone D, Shayakhmetov D, Kiviat N, Touré P, Sow S, Horvat B, Lieber A. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol. Ther. 2006;13(4):756-765. https://doi.org/10.1016/j.ymthe.2005.12.008
Duraikannu A, Krishnan A, Chandrasekhar A, Zochodne DW. Beyond trophic factors: exploiting the intrinsic regenerative properties of adult neurons. Front. Cell Neurosci. 2019;13:128. https://doi.org/10.3389/fncel.2019.00128
Enomoto M. Therapeutic effects of neurotrophic factors in experimental spinal cord injury models. J. Neurorestoratol. 2016;(1):15-22. https://doi.org/10.2147/JN.S66874
Keefe KM, Sheikh IS, Smith GM. Targeting neurotrophins to specific populations of neurons: NGF, BDNF, and NT-3 and their relevance for treatment of spinal cord injury. Int. J. Mol. Sci. 2017;18(3):548. https://doi.org/10.3390/ijms18030548
Razi Soofiyani S, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L. Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv. Pharm. Bull. 2013;3(2):249-255. https://doi.org/10.5681/apb.2013.041
Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol. Ther. 2020;28(3):709-722. https://doi.org/10.1016/j.ymthe.2020.01.001
Silvestro S, Bramanti P, Trubiani O, Mazzon E. Stem cells therapy for spinal cord injury: an overview of clinical trials. Int. J. Mol. Sci. 2020;21(2):659. https://doi.org/10.3390/ijms21020659.
Stepanenko AA, Sosnovtseva AO, Valikhov MP, Chekhonin VP. A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation. Sci. Rep. 2021;11(1):16088. https://doi.org/10.1038/s41598-021-94573-y
Stepanova OV, Voronova AD, Sosnovtseva AO, Stepanenko AA, Chadin AV, Karsuntseva EK, Fursa GA, Valikhov MP, Semkina AS, Vorobyev PO, Reshetov IV, Chekhonin VP. Study of the Therapeutic Efficiency of transduced olfactory ensheathing cells in spinal cord cysts. Stem Cells Dev. 2022;31(1-2):9-17. https://doi.org/10.1089/scd.2021.0265
Uchida K, Nakajima H, Guerrero AR, Johnson WE, Masri WE, Baba H. Gene therapy strategies for the treatment of spinal cord injury. Ther. Deliv. 2014;5(5):591-607. https://doi.org/10.4155/tde.14.20
Voronova АD, Stepanova OV, Valikhov MP, Chadin AV, Dvornikov АS, Reshetov IV, Chekhonin VP. Preparation of human olfactory ensheathing cells for the therapy of spinal cord injuries. Bull. Exp. Biol. Med. 2018;164(4):523-527. https://doi.org/10.1007/s10517-018-4025-x
Voronova AD, Stepanova OV, Chadin AV, Fursa GA, Karsuntseva EK, Valikhov MP, Semkina АS, Reshetov IV, Chekhonin VP. The effect of transplantation of olfactory ensheathing cells on the size of posttraumatic spinal cord cysts. Bull. Exp. Biol. Med. 2021;171(1):122-126. https://doi.org/10.1007/s10517-021-05183-7
Wang L, Yang P, Liang X, Ma L, Wei J. Comparison of therapeutic effects of olfactory ensheathing cells derived from olfactory mucosa or olfactory bulb on spinal cord injury mouse models. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014;30(4):379-383.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 2, pp. 84-89, June, 2022
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Voronova, A.D., Sosnovtseva, A.O., Stepanova, O.V. et al. Obtaining a New Gene-Cell Construct Based on Transduced Olfactory Ensheathing Cells for the Treatment of Spinal Cord Injuries. Bull Exp Biol Med 173, 529–533 (2022). https://doi.org/10.1007/s10517-022-05576-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-022-05576-2